Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19

The COVID-19 pandemic is an ongoing global pandemic of coronavirus disease 2019 as an atypical type of viral pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many potential pharmacotherapies are currently being investigated against this disease. This article points t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Amani E. Khalifa, PhD, Asser I. Ghoneim, PhD, PharmD
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Agonists Antagonists COVID-19 TLR7 TLR8 Vaccines Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/c9c5eb814fe3485b97f0ef66eb4600a3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c9c5eb814fe3485b97f0ef66eb4600a3
record_format	dspace
spelling	oai:doaj.org-article:c9c5eb814fe3485b97f0ef66eb4600a32021-11-10T04:41:05ZPotential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-192590-257110.1016/j.crphar.2021.100068https://doaj.org/article/c9c5eb814fe3485b97f0ef66eb4600a32021-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2590257121000559https://doaj.org/toc/2590-2571The COVID-19 pandemic is an ongoing global pandemic of coronavirus disease 2019 as an atypical type of viral pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many potential pharmacotherapies are currently being investigated against this disease. This article points to and justifies, the importance of investigating the potential therapeutic value of pharmacological agents acting on Toll-like Receptor (TLR) 7 and/or TLR8 as double-edged swords combating COVID-19. Induction of TLR7 and/or TLR8 may be investigated as a strategy to stimulate immunity and may be added to anti-COVID19 vaccines to cope with their current viral escape challenge. TLR7 stimulation may not only help viral clearance through Th1 antiviral responses but may also provide beneficial broncho- and vaso-dilatory, as well as, anti-inflammatory effects. Pharmacological compounds acting as TLR7 and/or TLR8 agonists may be of value if used by frontline healthcare workers with comorbidities who demonstrate mild symptoms of the disease. On the other hand, TLR7 and/or TLR8 antagonists may be used in combination with immune-modulatory/anti-inflammatory drugs in severe cases of the disease, with potential synergistic effects that could also help in reducing the doses of such therapies, and consequently their adverse effects.Amani E. Khalifa, PhDAsser I. Ghoneim, PhD, PharmDElsevierarticleAgonistsAntagonistsCOVID-19TLR7TLR8VaccinesTherapeutics. PharmacologyRM1-950ENCurrent Research in Pharmacology and Drug Discovery, Vol 2, Iss , Pp 100068- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Agonists Antagonists COVID-19 TLR7 TLR8 Vaccines Therapeutics. Pharmacology RM1-950
spellingShingle	Agonists Antagonists COVID-19 TLR7 TLR8 Vaccines Therapeutics. Pharmacology RM1-950 Amani E. Khalifa, PhD Asser I. Ghoneim, PhD, PharmD Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19
description	The COVID-19 pandemic is an ongoing global pandemic of coronavirus disease 2019 as an atypical type of viral pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many potential pharmacotherapies are currently being investigated against this disease. This article points to and justifies, the importance of investigating the potential therapeutic value of pharmacological agents acting on Toll-like Receptor (TLR) 7 and/or TLR8 as double-edged swords combating COVID-19. Induction of TLR7 and/or TLR8 may be investigated as a strategy to stimulate immunity and may be added to anti-COVID19 vaccines to cope with their current viral escape challenge. TLR7 stimulation may not only help viral clearance through Th1 antiviral responses but may also provide beneficial broncho- and vaso-dilatory, as well as, anti-inflammatory effects. Pharmacological compounds acting as TLR7 and/or TLR8 agonists may be of value if used by frontline healthcare workers with comorbidities who demonstrate mild symptoms of the disease. On the other hand, TLR7 and/or TLR8 antagonists may be used in combination with immune-modulatory/anti-inflammatory drugs in severe cases of the disease, with potential synergistic effects that could also help in reducing the doses of such therapies, and consequently their adverse effects.
format	article
author	Amani E. Khalifa, PhD Asser I. Ghoneim, PhD, PharmD
author_facet	Amani E. Khalifa, PhD Asser I. Ghoneim, PhD, PharmD
author_sort	Amani E. Khalifa, PhD
title	Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19
title_short	Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19
title_full	Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19
title_fullStr	Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19
title_full_unstemmed	Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19
title_sort	potential value of pharmacological agents acting on toll-like receptor (tlr) 7 and/or tlr8 in covid-19
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/c9c5eb814fe3485b97f0ef66eb4600a3
work_keys_str_mv	AT amaniekhalifaphd potentialvalueofpharmacologicalagentsactingontolllikereceptortlr7andortlr8incovid19 AT asserighoneimphdpharmd potentialvalueofpharmacologicalagentsactingontolllikereceptortlr7andortlr8incovid19
_version_	1718440597403992064

Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19

Ejemplares similares